OncoSec Medical Inc (ONCSQ)

[dangerM]

Not worried either :o)

I'd be somewhat worried if I was holding BMY/NKTR (because of Oncosec, but also other reasons I might explain on another board someday ;) I'd also feel somewhat more fraught if I was holding LOXO, since it appears there will be good data about entrectinib against ROS1* at WCLC.


Still, I expect a focus on biomarker data. If they show some response data (even interim response data) I don't think it'll be for the whole study population of part I.



* not to be confused with ROS, here it's ROS1, the mutation